Core Insights - Haemonetics is well-positioned to continue its earnings-beat streak, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 11.15% [1] Earnings Performance - In the last reported quarter, Haemonetics achieved earnings of $1.27 per share, surpassing the Zacks Consensus Estimate of $1.12 per share, resulting in a surprise of 13.39% [2] - In the previous quarter, the company was expected to report earnings of $1.01 per share but delivered $1.10 per share, yielding a surprise of 8.91% [2] Earnings Estimates - There has been a favorable change in earnings estimates for Haemonetics, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests that stocks with this profile beat consensus estimates nearly 70% of the time [6] Earnings ESP Analysis - Haemonetics currently has an Earnings ESP of +0.79%, indicating that analysts have recently become more optimistic about the company's earnings prospects [8] - The next earnings report for Haemonetics is expected to be released on February 5, 2026 [8]

Company Performance - Haemonetics reported quarterly earnings of $1.24 per share, exceeding the Zacks Consensus Estimate of $1.22 per share, and up from $0.90 per share a year ago [1] - The company posted revenues of $330.6 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1%, but down from $343.29 million year-over-year [3] - The earnings surprise for this quarter was 1.64%, and Haemonetics has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Haemonetics shares have declined approximately 17.7% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [4] - The current Zacks Rank for Haemonetics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $315.05 million, and for the current fiscal year, it is $4.98 on revenues of $1.32 billion [8] - The estimate revisions trend for Haemonetics is mixed, and changes in earnings expectations may occur following the recent earnings report [5][7] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9]